<code id='9848465DE6'></code><style id='9848465DE6'></style>
    • <acronym id='9848465DE6'></acronym>
      <center id='9848465DE6'><center id='9848465DE6'><tfoot id='9848465DE6'></tfoot></center><abbr id='9848465DE6'><dir id='9848465DE6'><tfoot id='9848465DE6'></tfoot><noframes id='9848465DE6'>

    • <optgroup id='9848465DE6'><strike id='9848465DE6'><sup id='9848465DE6'></sup></strike><code id='9848465DE6'></code></optgroup>
        1. <b id='9848465DE6'><label id='9848465DE6'><select id='9848465DE6'><dt id='9848465DE6'><span id='9848465DE6'></span></dt></select></label></b><u id='9848465DE6'></u>
          <i id='9848465DE6'><strike id='9848465DE6'><tt id='9848465DE6'><pre id='9848465DE6'></pre></tt></strike></i>

          
          WSS
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive